Lipigon Pharmaceuticals AB (publ) (LPGO.ST)
SEK 0.1
(-21.67%)
SEK 0.1
(-21.67%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 33.6 Million SEK | 210.67% |
| 2022 | 10.81 Million SEK | -63.25% |
| 2021 | 29.42 Million SEK | 93.07% |
| 2020 | 15.24 Million SEK | 374.83% |
| 2019 | 3.21 Million SEK | 1326.67% |
| 2018 | 225 Thousand SEK | -99.99% |
| 2017 | 1.77 Billion SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 25.76 Million SEK | -23.32% |
| 2024 Q2 | 30.31 Million SEK | 17.64% |
| 2023 Q1 | 4.77 Million SEK | -55.88% |
| 2023 Q3 | 26.86 Million SEK | -23.51% |
| 2023 FY | 33.6 Million SEK | 210.67% |
| 2023 Q4 | 33.6 Million SEK | 25.09% |
| 2023 Q2 | 35.11 Million SEK | 635.92% |
| 2022 Q3 | 16.83 Million SEK | -47.2% |
| 2022 Q1 | 19.02 Million SEK | -35.34% |
| 2022 FY | 10.81 Million SEK | -63.25% |
| 2022 Q4 | 10.81 Million SEK | -35.75% |
| 2022 Q2 | 31.87 Million SEK | 67.54% |
| 2021 Q1 | 61.8 Million SEK | 305.47% |
| 2021 FY | 29.42 Million SEK | 93.07% |
| 2021 Q4 | 29.42 Million SEK | -28.65% |
| 2021 Q3 | 41.24 Million SEK | -22.54% |
| 2021 Q2 | 53.24 Million SEK | -13.85% |
| 2020 FY | 15.24 Million SEK | 374.83% |
| 2020 Q4 | 15.24 Million SEK | 0.0% |
| 2020 Q1 | - SEK | 0.0% |
| 2019 FY | 3.21 Million SEK | 1326.67% |
| 2018 FY | 225 Thousand SEK | -99.99% |
| 2017 FY | 1.77 Billion SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Active Biotech AB (publ) | 44 Million SEK | 23.632% |
| Biovica International AB (publ) | 131.4 Million SEK | 74.429% |
| Cantargia AB (publ) | 223.71 Million SEK | 84.98% |
| CombiGene AB (publ) | 120.61 Million SEK | 72.14% |
| Cyxone AB (publ) | 43.65 Million SEK | 23.028% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -17.869% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -11.364% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | 57.299% |
| Fluicell AB (publ) | 9.34 Million SEK | -259.764% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 90.436% |
| Mendus AB (publ) | 755.95 Million SEK | 95.555% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 76.1% |
| I-Tech AB | 152.44 Million SEK | 77.958% |
| Intervacc AB (publ) | 259.61 Million SEK | 87.057% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 87.945% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -67.666% |
| OncoZenge AB (publ) | 20.34 Million SEK | -65.202% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | 46.131% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 94.858% |
| Lipum AB (publ) | 12.11 Million SEK | -177.473% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 71.632% |
| Ziccum AB (publ) | 14.97 Million SEK | -124.432% |
| BioArctic AB (publ) | 1.18 Billion SEK | 97.167% |
| Genovis AB (publ.) | 288.85 Million SEK | 88.367% |
| Camurus AB (publ) | 1.9 Billion SEK | 98.239% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 81.029% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | 45.936% |
| Aptahem AB (publ) | 63.02 Million SEK | 46.685% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 93.229% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 95.609% |
| Kancera AB (publ) | 65.64 Million SEK | 48.811% |
| Saniona AB (publ) | 64.14 Million SEK | 47.614% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | 36.582% |
| AcouSort AB (publ) | 34.51 Million SEK | 2.64% |
| Xintela AB (publ) | 18.39 Million SEK | -82.669% |
| Abliva AB (publ) | 87.49 Million SEK | 61.597% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 97.33% |
| Amniotics AB (publ) | 26.08 Million SEK | -28.812% |
| 2cureX AB (publ) | 16.62 Million SEK | -102.117% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -452.937% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 98.232% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 96.699% |
| Biosergen AB | 7.2 Million SEK | -366.63% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | 19.917% |
| Corline Biomedical AB | 100.1 Million SEK | 66.433% |
| NextCell Pharma AB | 81.28 Million SEK | 58.663% |
| Nanologica AB (publ) | 77.42 Million SEK | 56.603% |
| LIDDS AB (publ) | 17.65 Million SEK | -90.326% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 95.58% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 97.6% |
| SynAct Pharma AB | 228.01 Million SEK | 85.264% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -25.554% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -54.827% |
| Alzinova AB (publ) | 123.18 Million SEK | 72.723% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 61.409% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 85.904% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -297.422% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 60.574% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -125.987% |
| Simris Alg AB (publ) | 174.55 Million SEK | 80.75% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 84.518% |